BioArctic

BioArctic LT Debt/Equity

The Long-Term Debt to Equity Ratio of BioArctic (BIOA B.ST) as of Nov 10, 2026 is 0.01. In the previous year, Long-Term Debt to Equity Ratio was 0.05 — a change of -68.60% (lower).

LT Debt/Equity

0.01

YoY

-68.60%

Last updated:

Long-Term Debt to Equity Ratio of BioArctic is 2025 0.01 . Long-Term Debt to Equity Ratio of BioArctic was 2024 0.05 . It decreases by -68.60% lower compared to the previous year.

The BioArctic LT Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

LT Debt/Equity
Date
LT Debt/Equity
Jan 1, 2018
0.00 SEK
Jan 1, 2019
0.02 SEK
Jan 1, 2020
0.02 SEK
Jan 1, 2021
0.01 SEK
Jan 1, 2022
0.00 SEK
Jan 1, 2023
0.00 SEK
Jan 1, 2024
0.05 SEK
Jan 1, 2025
0.01 SEK
The BioArctic LT Debt/Equity history
YEARLT Debt/EquityYoY
0.01-68.60%
0.05+2,132.30%
0.00+36.78%
0.00-84.77%
0.01-34.28%
0.02-30.06%
0.02—
0.00—
0.00—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Long-Term Debt to Equity Ratio of BioArctic is 0.01 in 2025.

Long-Term Debt to Equity Ratio of BioArctic changed from 0.05 to 0.01, representing a -68.60% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio BioArctic since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's BioArctic with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — BioArctic

All Key Metrics — BioArctic